Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection

Objectives:Among a subgroup of participants in the Strategies for Management of Antiretroviral Therapy (SMART) Trial that were naïve to antiretroviral therapy (ART) or off ART (6 months or longer) at study entry, risk of AIDS and serious non-AIDS events were increased for participants who deferred ART compared with those randomized to (re)initiate ART immediately. Our objective was to determine whether ART initiation in this group reduced markers of inflammation and coagulation that have been associated with increased mortality risk in SMART. Changes in these biomarkers have been described after stopping ART, but not after starting ART in SMART. Methods:Stored specimens for 254 participants (126 drug conservation [DC] and 128 viral suppression [VS]) who were naïve to ART or off ART (6 months or longer) were analyzed for interleukin-6, high sensitivity C-reactive protein, and D-dimer at baseline and Months 2 and 6. Results:At Month 6, 62% of the VS group had HIV RNA less than 400 copies/mL and median CD4 count was 190 cells/mm3 higher than for the DC group (590 versus 400 cells/mm3). Compared with DC, the VS group had 32% (95% confidence interval, 19%-43%) lower D-dimer levels at Month 6 (P < 0.001); differences were not significant for high sensitivity C-reactive protein or interleukin-6 levels. Conclusions:In this randomized comparison of immediate versus delayed ART initiation, D-dimer, but not interleukin-6 and high sensitivity C-reactive protein, declined significantly after starting ART. Further studies are needed to determine whether improvements in D-dimer are associated with reduced risk of clinical disease and whether adjunct treatments used in combination with ART can reduce inflammation among individuals with HIV infection.

[1]  D. Jacobs,et al.  Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. , 2010, The Journal of infectious diseases.

[2]  M. Lederman,et al.  Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. , 2010, Blood.

[3]  J. Morrow,et al.  Highly Sensitive C-Reactive Protein, Body Mass Index, and Serum Lipids in HIV-Infected Persons Receiving Antiretroviral Therapy: A Longitudinal Study , 2009, Journal of acquired immune deficiency syndromes.

[4]  M. King,et al.  Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. , 2009, The Journal of infectious diseases.

[5]  Jeffrey N. Martin,et al.  Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis , 2009, AIDS.

[6]  B. Hirschel,et al.  HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial , 2009, AIDS.

[7]  P. Reiss,et al.  Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. , 2009, The Journal of infectious diseases.

[8]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[9]  J. Lundgren.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients , 2008, AIDS.

[10]  A. Phillips,et al.  Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. , 2008, Annals of internal medicine.

[11]  H. Stellbrink,et al.  Increased Interferon Alpha Expression in Circulating Plasmacytoid Dendritic Cells of HIV-1-Infected Patients , 2008, Journal of acquired immune deficiency syndromes.

[12]  C. Sabin,et al.  Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. , 2008, Circulation.

[13]  C. Lewis,et al.  Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels: The Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study , 2008, Journal of acquired immune deficiency syndromes.

[14]  D. Fearon,et al.  Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. , 2008, Circulation.

[15]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[16]  W. K. Henry,et al.  CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection , 2008, AIDS.

[17]  J. Gatell,et al.  Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. , 2008, The Journal of infectious diseases.

[18]  Vilmundur Gudnason,et al.  Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.

[19]  C. Lewis,et al.  Association of antiretroviral therapy with fibrinogen levels in HIV-infection , 2008, AIDS.

[20]  H. Nielsen,et al.  Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[21]  V. Appay,et al.  Immune activation and inflammation in HIV‐1 infection: causes and consequences , 2008, The Journal of pathology.

[22]  O. Kirk,et al.  Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.

[23]  Richard D Moore,et al.  Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3 , 2007, Journal of acquired immune deficiency syndromes.

[24]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[25]  T. Buchanan,et al.  Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy , 2007, Cardiovascular Toxicology.

[26]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[27]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[28]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[29]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[30]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[31]  JohnYarnell,et al.  Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke , 2005 .

[32]  G. Lowe,et al.  Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?: The Caerphilly Study , 2005, Circulation.

[33]  A. Varin,et al.  HIV and inflammation. , 2005, Current HIV research.

[34]  G. Behrens.  Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.

[35]  E. Frenkel,et al.  Thrombosis and a Hypercoagulable State in HIV-Infected Patients , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[36]  R. Tracy.  Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. , 2003, Chest.

[37]  H. Cohen,et al.  Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. , 2003, The American journal of medicine.

[38]  R. Weber,et al.  Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. , 2002, The Journal of infectious diseases.

[39]  F. Bussolino,et al.  Interactions between endothelial cells and HIV-1. , 2001, The international journal of biochemistry & cell biology.

[40]  M. Saif,et al.  HIV and thrombosis: a review. , 2001, AIDS patient care and STDs.

[41]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[42]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[43]  L. Kuller,et al.  Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. , 1999, American journal of epidemiology.

[44]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.